Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AB
AbCellera Biologics Inc. Common Shares
ABCL
Mkt Cap
$3.83B
Volume
3.73M
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AB
ABCL
AB
AbCellera Biologics Inc. Common Shares
ABCL
News
·
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates
Mkt Cap
$4.11B
Volume
3.73M
Next Earnings
November 9th
Chart
Financials
Earnings
News
About
Insider
Filings
Nurix Therapeutics, Inc. (NRIX) Q3 Earnings and Revenues Surpass Estimates
Nurix Therapeutics reported Q3 2026 earnings of $4.73 per share, significantly beating the consensus estimate of a loss of $0.56 per share, with a 944.64% earnings surprise. Revenues reached $673.06 million, surpassing estimates by 383.11%. However, the stock received a Zacks Rank #3 (Hold) rating, with mixed estimate revisions and the company's industry ranking in the bottom 33% of sectors.
Zacks Investment Research · Oct 12, 2026
Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera
The global synthetic antibody library market is projected to grow from $1.63 billion in 2025 to $2.86 billion by 2030, representing a 12% CAGR. Growth is driven by AI-integrated antibody design, increased demand for therapeutic antibodies, high-throughput screening technologies, and expansion of contract research organizations. North America leads the market while Asia-Pacific shows fastest growth potential.
GlobeNewswire Inc. · Oct 12, 2026
Prelude Cuts Q2 Losses and Costs 13%
Prelude Therapeutics reported a Q2 2025 net loss of $31.2 million, reduced operating expenses, and focused on its oral SMARCA2 degrader program while maintaining cash reserves to fund operations into Q2 2026.
The Motley Fool · Aug 14, 2025
Global Antibody Discovery Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight
The antibody discovery market is projected to grow at a 10% CAGR by 2032, driven by increasing chronic disease incidence, biologics adoption, and technological advancements in drug development.
GlobeNewswire Inc. · Jul 30, 2025
Down 57%, Is AbCellera Biologics a Buy on the Dip?
Wall Street analysts say this drug developer can more than double your money.
The Motley Fool · Jun 13, 2024
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript
ABCL earnings call for the period ending March 31, 2024.
The Motley Fool · May 8, 2024
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
AbCellera Biologics (ABCL) delivered earnings and revenue surprises of 12.50% and 11.64%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research · May 7, 2024
Cytokinetics (CYTK) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research · May 1, 2024
Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for
AbCellera Biologics (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research · Apr 30, 2024
AbCellera Biologics (ABCL) Q4 2023 Earnings Call Transcript
ABCL earnings call for the period ending December 31, 2023.
The Motley Fool · Feb 21, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AB
ABCL
AbCellera Biologics Inc. Common Shares
Buy
Sell
Market
Limit
Soon
ABCL
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any ABCL yet.
Related Tickers
Earnings